Large-scale examination of neuropsychiatric, cognitive and cardiovascular phenotypic associations with 15q11.2 BP1-BP2 deletion in ~500,000 UK Biobank individuals
Simon G. WilliamsiD, Apostol NakeviD, Hui GuoiD, Simon FrainiD, Gennadiy TeniniD, Anna Liakhovitskaia, Priyanka SahaiD, James Rush PriestiD, Kathryn E. HentgesiD, Bernard D. KeavneyiD
Abstract
BackgroundDeletion of a non-imprinted 500Kb genomic region at chromosome 15q11.2, between breakpoints 1 and 2 of the Prader-Willi/Angelman locus (BP1-BP2 deletion) has been associated in previous studies with phenotypes including developmental delay, autism, schizophrenia and congenital cardiovascular malformations (CVM). The deletion has a low baseline population prevalence and large-scale data regarding the magnitude of these associations and any milder effects on cognition phenotypes, in populations not selected for disease, are limited.\n\nMethodsUsing the UK Biobank (UKB) cohort of [~]500,000 individuals, we identified individuals with neuropsychiatric and CVM diagnoses and investigated their association with deletions at the BP1-BP2 locus. In addition we assessed the association of BP1-BP2 deletions with cognitive function and academic achievement in individuals with no previous diagnosis.\n\nResultsCases of neurodevelopmental and CVM disease had an increased prevalence of the deletion compared to controls (0.68%; OR=1.84 [95% CI 1.23 - 2.75]; p=0.004 and 0.64%; OR=1.73 [95% CI 1.08 - 2.75]; p=0.03 respectively). Excluding participants diagnosed with neurodevelopmental or neuropsychiatric disease, deletion carriers had worse scores in four tests of cognitive function, and while 32.8% of UKB participants without BP1-BP2 deletion had a university or college degree as their highest educational qualification, only 22.8% of deletion carriers achieved this (OR 0.57 [95% CI 0.51-0.64]; p=5.60E-22).\n\nConclusionsWe conclude that BP1-BP2 deletion has an appreciable population prevalence with important life-course impacts on undiagnosed carriers. These data are of potential utility in deciding the circumstances under which clinical testing for BP1-BP2 deletion may be helpful.\n\nKey messagesO_LIDeletions at chromosome 15q11.2 between breakpoints 1 and 2 (BP1-BP2), which encompass four genes, have been associated with developmental delay, autism, schizophrenia and congenital cardiovascular malformations.\nC_LIO_LIHere, we use the largest cohort studied to date: the UK Biobank cohort of [~]500,000 individuals, to explore the association of this deletion with neuropsychiatric and cardiovascular phenotypes as well as its effects on cognitive function and academic achievement.\nC_LIO_LIWe find an appreciable population prevalence of the deletion with these phenotypes and demonstrate reduced cognitive function and lower academic achievements in those individuals with no prior diagnosis.\nC_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Analysis of diffusion tensor imaging data from UK Biobank confirms dosage effect of 15q11.2 copy-number variation on white matter and shows association with cognition
Ana Isabel Silva, George Kirov, … Xavier Caseras·Biological PsychiatryPeer-reviewed·Mar 3, 2021
- Variable penetrance of the 15q11.2 BP1-BP2 microduplication in a family with cognitive and language impairment
Antonio Benítez‐Burraco, Montserrat Barcos, … Ma Salud Jiménez-Romero·Molecular SyndromologyPeer-reviewed·Jan 1, 2017
- The Neuropsychiatry of 22q11.2 Deletion Syndrome: An Electronic Health Records Study.
Cameron James Watson, Maria Rogdaki, … Thomas Arthur Pollak·medRxiv·Aug 4, 2026
- Unique functional neuroimaging signatures of genetic versus clinical high risk for psychosis
Charles H. Schleifer, Sarah E. Chang, … Carrie E. Bearden·Biological PsychiatryPeer-reviewed·Aug 23, 2024
- Disentangling mechanisms behind the pleiotropic effects of proximal 16p11.2 BP4-5 CNVs
Chiara Auwerx, Samuel Moix, … Alexandre Reymond·The American Journal of Human GeneticsPeer-reviewed·Sep 26, 2024
- Functional consequences of genetic risk for neuropsychiatric conditions at chr22q
Ajay Nadig, Matthew Tegtmeyer, … Elise Robinson·medRxiv·Jul 1, 2025